Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

“Multi-Omic” Diagnostic Test Will Accelerate Implementation of Personalized Healthcare

By Labmedica International staff writers
Posted on 06 Mar 2013
Personalized healthcare, giving the appropriate therapy to the individual patient, depends on high-value diagnostics that can guide “which patients” will respond to “which therapy” within a specific disease.

Sylventa (Cambridge, MA, USA) is developing Systems Diagnostics (SysDx) a novel diagnostic test that can consist of “multi-omic” biomarkers selected through a rigorous Big Data analysis of a patient’s biological profile including genomic, epigenomic, transcriptomic, proteomic, metabolomic, and electronic medical record information.

From this analysis, Selventa will generate a differentiated and clinically relevant report that physicians and patients can use to improve therapy selection.

Most chronic diseases, including asthma, diabetes, Parkinson’s disease, late-onset Alzheimer’s disease, and most cancers, are too complex to rely on genomic variations alone. Instead, the molecular drivers of disease are manifested across thousands of interrelated, biochemical pathways and these disease-drivers need to be thoroughly interrogated in order to provide effective treatment options.

Dr. David de Graaf, president and CEO Selventa, remarked, “SysDx is a natural outgrowth of our successful 10-year heritage as a leader in systems biology and biomarker identification for pharma and biotech. Our ‘Big Data’ analytics and algorithms uniquely integrate, process, and analyze different molecular information from thousands of patients to identify biomarkers. This unique capability is the foundation for SysDx tests that will have stronger validation, higher reliability, and provide superior predictive and prognostic capabilities.”

Selventa is currently focusing its SysDx development in autoimmune diseases and cancer. These complex multifactorial diseases require more than genetic information alone to gain an effective diagnosis that can guide treatment. Selventa’s lead product will be Clarify-RA, a SysDx test that will be able to predict which patients suffering from rheumatoid arthritis (RA) will not respond to the standard of care antitumor necrosis factor (TNF) therapy. RA is a chronic, debilitating disease that affects an estimated 2 million people in the United States. It is also an expensive disease to treat, costing the healthcare system on average USD 20,000 per patient every year. In moderate to severe RA patients, only 40% of patients gain a clinically significant benefit from the anti-TNFs.

Related Links:

Selventa




MEDLAB Asia
KARL HECHT GMBH & CO KG
CELLAVISION AB
PERIPHERAL VISIONS INC

Channels

Clinical Chemistry

view channel
Image: UniCel DxC 800 Synchron Clinical Systems (Photo courtesy of Beckman Coulter).

Routine Blood Glucose Value Correlates with Diabetes Risk

Random glucose values obtained during routine blood tests are often overlooked, but could provide valuable insight into whether someone is at risk for having type 2 diabetes. Random Blood Glucose (RBG)... Read more

Hematology

view channel
Image: Plastic bag containing 0.5 to 0.7 liters of packed red blood cells in citrate, phosphate, dextrose, and adenine (CPDA) solution (Photo courtesy of Fresenius HemoCare).

Transfusion Protocols Compared After Cardiac Surgery

Unnecessary blood transfusions may increase healthcare costs both directly, because blood is an increasingly scarce and expensive resource, and indirectly due to the complications associated with transfusion.... Read more

Industry News

view channel

Sequencing-Based Testing Sector Already Highly Competitive

As next-generation sequencing (NGS) reaches the clinical laboratory, a new analysis by Kalorama Information (New York, NY, USA) finds that small reference laboratories as well as over 50 companies now offer sequencing-based testing through their own CLIA-certified laboratories, some of which offer a wide range of tests.... Read more
 

Events

28 Mar 2015 - 01 Apr 2015
06 Apr 2015 - 08 Apr 2015
07 Apr 2015 - 09 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.